Unprecedented challenges now facing sponsors in bringing new medicines to market are beginning to speed pharmaceutical companies’ notoriously slow pace of approaching change. Rapidly rising R&D costs and low clinical success rates have spurred some of the industry’s largest companies to begin to think out-of-the-box and create new programs to improve the efficiency of the clinical research process, lower expenses and increase productivity...
Private equity interest in CROs could lead to more IPOs
Private equity and medium to top-tier CROs have been a match made in heaven over the last several years. Equity players look for investments that will grow in value while being self-sustaining and producing a great deal of cash, and CROs fit the bill. And medium to top-tier CROs need financial partners to enable them to acquire and hire to grow larger and attract more clients and better contracts, which private equity investors provide…
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.
